Chris Holden

I'm Chris, and This is My Blog

Healthcare Investment Titans Jacob Gottlieb and Stuart Weisbrod Reunite Forces

by Chris Holden - August 16th, 2018.
Filed under: Investment.

Shaking the healthcare investment sector, two industry giants Jacob Gottlieb and Stuart Weisbord have reunited forces on a project that is yet to unfold.

Each of these investment professionals has a rich history of credibility in their field. Weisbrod saw his beginnings in academics. Graduating with his BA in Chemistry from Colgate University, he was a persistent student. He went on to earn a PhD in Biochemistry from Princeton University in 1980, but he didn’t stop there. Weisbrod then gained his MBA in Finance from Columbia University in 1986. Backed by an incredible education, he worked with major investment companies, such as Oracle Partners, Harpel Partners, and Merrill Lynch.

Now with over twenty years of academic and professional healthcare investment know-how beneath his belt, Weisbrod went on to co-found the biotechnology investment company Merlin in 1998. The firm was highly successful, as Weisbrod built a team inevitably bound for prosperity. One key player on Weisbrod’s team was Jacob Gottlieb, who worked as portfolio manager in 2000. Merlin saw returns of over one hundred percent in 1999 and 2000, earning the respect in the industry necessary for accruing distinguished clients. Major pension funds, family-run offices, endowments, and those with high net worth saw the growth of Merlin and felt inclined to opt in as clients.

But Weisbrod, ever striving to achieve his greatest in his sector, exceeded his success with Merlin to found Iguana Healthcare Partners. The firm focuses on publically-owned companies in healthcare, with an emphasis on versatility in changing conditions.

Gottlieb, similarly, founded his very own firm after working with Merlin. Gottlieb’s company, Visium Assett Management, grew from a $300 million to $2.5 billion by 2008, and then to $8 billion in 2008. Come 2016, Visium’s monumental success halted, as three executives suffered accusations of insider trading and mismarking. In the wake of resulting FBI and U.S. Securities and Exchange Commission investigations, Gottlieb was never charged and made valiant effort to return all funds to investors. Given both Weisbrod and Gottlieb’s seasoned experience in healthcare investment, their new collaboration is sure to yield incredible progress in the investment world.

Leave a Reply

You must be logged in to post a comment.